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Human liver mRNA isolated from subjects phenotyped as homozygous PiMM or PiZZ cYr-antitrypsin, was 
translated in a reticulocyte cell-free system, and ar-antitrypsin identified by immunoprecipitation. In the 
presence of dog pancreas membranes the translated cYr-antitrypsin appeared as a larger product. Treatment 
with endo-,&-N-glucosaminidase yielded a protein smaller than the reticulocyte translated product, 
presumably due to removal of the N-terminal signal sequence by membranes and sugar residues by endo- 
/?-N-glucosaminidase. Quantitation of al-antitrypsin translated from PiMM and PiZZ livers suggests hat 
both mRNA species were present at the same cellular concentration, and that processing to the core 
glycosylation stage proceeded at identical rates. 
al-Antitrypsin In vitro translation 
1. INTRODUCTION 
ar-Antitrypsin is a glycoprotein of A4, 51000 
which functions as the major serine proteinase in- 
hibitor in plasma. The structure, function and 
common abnormalities have been recently review- 
ed [l]. The common Z variant results in a plasma 
concentration in the PiZZ homozygote of about 
15% of the PiMM normal. Studies measuring the 
half-life of circulating Z protein have excluded an 
increased rate of degradation [2] and it is likely 
therefore that the low plasma concentration results 
from either a decreased level of synthesis or from 
faulty processing. In this study, using cell-free 
systems, we have shown that the rates of -transla- 
tion of M and Z mRNA and of translocation and 
core glycosylation of the two polypeptides are 
equivalent. 
2. MATERIALS AND METHODS 
L-[35S]%ethionine (700-1300 Ci/mmol) was ob- 
tained from Amersham; Oligo(dT)-cellulose (type 
2) from Collaborative Research; Enhance and r4C- 
In vitro processing Human liver mRNA 
labelled MI standards from New England Nuclear. 
All other enzymes and chemicals were obtained 
from sources already described [3,4]. 
Human liver was obtained as in [5,6] and stored 
at - 80°C until used. The RNA was isolated by the 
direct phenol method [7,8] and the poly(A)- 
containing RNA species purified by binding twice 
to oligo(dT)-cellulose at 400 mM NaCl without 
prior removal of DNA [6]. In vitro translation of 
mRNA was performed in a nuclease-treated rabbit 
reticulocyte lysate [9, lo]. Incubations were for 
90 min at 35°C and in some experiments nuclease- 
treated dog pancreas membranes [ 1 l] were present 
at a final concentration of 2.3 &50 units/ml. 
a,-Antitrypsin was immunoprecipitated from 
translation assays as in [ 121 using monospecific an- 
tisera prepared in rabbits. Antibody precipitated 
translation products were analysed on 
SDS-polyacrylamide gel slabs using fluorographic 
enhancement [ 131. Endo-fl-N-glucosaminidase was 
purchased from Miles Laboratories, USA. Diges- 
tion was carried out as in [13] in the presence of 
PMSF as a protease inhibitor. 
270 
Published by Elsevier Biomedical Press 
00145793/83/0000-0000/$3.00 0 Federation of European Biochemical Societies 
Volume 153, number 2 FEBS LETTERS March 1983 
3. RESULTS AND DISCUSSION 
Human liver mRNA was isolated in yields vary- 
ing from 25 pg to 60 pg mRNA/g wet wt tissue 
(1 A260 = 40 pg). Reticulocyte 1ySate cell-free syn- 
thesis was optimised for the translation of human 
liver mRNA. Maximum stimulation was achieved 
at a final [K+] 110 mM with [MS”] 1.65 mM. The 
addition of human placenta ribonuclease inhibitor 
[ 141 had no effect on either the stimulation of total 
protein synthesis or on the SDS-polyacrylamide 
gel profile. 
When mRNA from both the PiMM and PiZZ 
phenotype livers was translated in the reticulocyte 
lysate system essentially identical stimulation was 
achieved (fig.lA). Maximum stimulation (4-10 x 
background) occurred at an mRNA concentration 
of 6.25 /rg/assay. The same mRNA concentration 
gave maximum stimulation in the presence of dog 
pancreas membranes, although in some cases the 
membrane preparations inhibited total protein 
synthesis by up to 40%. cui-Antitrypsin production 
was assayed by antibody precipitation (fig.lB) and 
again maximum stimulation occurred at an mRNA 
concentration of 6.25 pg/assay. Yields varied from 
1.5-3.5070 of total protein synthesised. No dif- 
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ference was noted in the amount of cui-antitrypsin 
synthesised in the presence of membranes, and no 
selective inhibition of either the M or Z 
cur-antitrypsin directed protein synthesis was 
observed. 
SDS-polyacrylamide gel electrophoresis was 
performed on the antibody precipitates to confirm 
that the ai-antitrypsin had undergone initial 
secretory processing by the membranes. Fig.2 
(lanes 2 and 3) shows the profile of PiMM and 
PiZZ al-antitrypsin translated in the reticulocyte 
lysate. The two tracks are identical with the major 
band having an app. M, 49000 and a second 
smaller product M, 46000. These bands were both 
confirmed as cui-antitrypsin by adding purified 
human cyi-antitrypsin to the translation mix prior 
to antibody precipitation. Both bands disappeared 
from the gel, indicating that both proteins were 
recognised by the cYi-antitrypsin antibody. A possi- 
ble explanation for the second, lower M, band is 
thiol-protease activity in the reticulocyte lysate 
which is known to cleave al-antitrypsin [15,16]. 
The gel profile of PiMM and PiZZ mRNA 
translated in the presence of membranes howed a 
single band at M, 59000 (fig.2, lanes 4 and 5). 
When the cell-free assays performed in the 
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Fig.1. Liver mRNA directed cell-free protein synthesis. mRNA from PiMM phenotype liver in the presence (o), or 
absence (0) of dog pancreas membranes. mRNA from PiZZ phenotype liver in the presence (A), or absence (A) of dog 
pancreas membranes: (A) total incorporation of [35S]methionine into trichloroacetic acid-precipitable polypeptides of 
both the M and the Z liver mRNA in the presence and absence of dog pancreas membranes; (B) incorporation of 
[35S]methionine into antibody-precipitable cY1-antitrypsin directed by both the M and Z liver mRNA, again in the 
presence and absence of dog pancreas membranes. 
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Fig.2. Fluorograph of SDS-polyacrylamide gel showing 
the synthesis of M and Z rur-antitrypsin. Antibody 
precipitates of al-antitrypsin synthesised from total liver 
mRNA in reticulocyte lysate with or without dog 
pancreas membranes were examined by 
SDS-polyacrylamide gel electrophoresis. Lane 1: A41 
distribution of 14C-labelled markers (5 ~1 of 5 &i/ml) 
(from the top of the gel): phosphorylase B (93000); 
bovine serum albumin (68000); ovalbumin (45000); 
carbonic anhydrase (30000); and lysozyme (14200). 
Lanes 2 and 3: antibody precipitated cur-antitrypsin 
synthesised in a reticulocyte lysate (lane 2, PiMM 
37000 cpm; lane 3, PiZZ 35000 cpm). Lanes 4 and 5: 
antibody-precipitated cur-antitrypsin synthesised in the 
presence of dog pancreas membranes (lane 4, PiMM 
26000 cpm; lane 5, PiZZ 27500 cpm). Lanes 6 and 7: 
aI-antitrypsin synthesised in the presence of dog 
pancreas membranes and treated with proteinase-K prior 
to antibody precipitation (lane 6, PiMM 21000 cpm; 
lane 7, PiZZ 21500 cpm). Lanes 8 and 9: antibody- 
precipitated (or-antitrypsin synthesised in the presence of 
dog pancreas membranes and treated with endo-P-N- 
glucosaminidase (lane 8, PiMM 6500 cpm; lane 9, PiZZ 
7200 cpm). 
presence of membranes were treated with 
proteinase-K prior to antibody precipitation [ 131 
(fig.2, lanes 6 and 7) this high M, protein remain- 
ed. When detergent was used to solubilise the 
membranes prior to the proteinase-K treatment, 
the protein was degraded. To confirm that the pro- 
tein M, 59000 which was resistant to proteolytic 
degradation in the absence of detergents, had 
undergone post-translational modification, 
antibody-precipitated material was subjected to 
endo-P-N-glucosaminidase digestion. As shown in 
fig.2 (lanes 8 and 9) this treatment reduced the M, 
of ai-antitrypsin to 47000 and is consistent with 
the removal of both the core sugar residues and the 
N-terminal signal sequence. 
In this process only 25% of the counts were 
recovered and a second experiment was performed 
to exclude the possibility that the single band 
observed was due to specific proteolytic cleavage. 
In this second experiment a different membrane 
preparation was used which appears to give slower 
post-translational processing. This produced 5 
distinct bands: the two of lowest M, coinciding 
with the unmodified ai-antitrypsin polypeptide as 
from a cell-free system, the remaining 3 being of 
greater than M, 49000 and compatible with the se- 
quential addition of each of the 3 carbohydrate 
sidechains known to be present in cur-antitrypsin 
[17] (fig.3). Treatment with endo-,0-N- 
glucosaminidase again reduced all 3 bands to a 
single band with an M, 47000, and a 50% yield of 
radioactivity. Had the product in lanes 8 and 9 of 
fig.2 been due to specific proteolytic cleavage then 
multiple bands should still have been observed in 
lanes 4 and 5 of fig.3. 
In PiZZ individuals, cYi-antitrypsin is onIy par- 
tially secreted and a considerable amount ac- 
cumulates in the endoplasmic reticulum of the 
hepatocytes. This accumulated protein has the 
same N-terminal sequence as the plasma form (per- 
sonal communication, J.-O. Jeppsson), but its car- 
bohydrate sidechains appear to be immature with 
a high mannose content and no sialic acid 118,191. 
This is compatible with the deficiency of the Z pro- 
tein being due to a partial block in secretion of the 
polypeptide with only a little of the material being 
fully glycosylated, and subsequently secreted into 
the plasma. Our previously published results [6] in- 
dicated that the levels of cur-antitrypsin mRNA as 
judged by translation in a wheatgerm system are 
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periments presented here we have demonstrated 
that the polypeptide is processed normally by the 
dog pancreas membranes resulting in the removal 
of the N-terminal signal sequence and addition of 
the core sugar residues. 
Fig.3. Fluorograph of SDS-polyacrylamide gel showing 
the post-translational modification of M and Z 
cYi-antitrypsin. Conditions of synthesis, preparation of 
mRNA, and antibody precipitation were as described for 
fig.2. Lane 1: M, distribution of 14C-labelled markers (as 
in lane 1, fig.2). Lanes 2 and 3: antibody-precipitated 
cui-antitrypsin synthesised in the presence of a second 
preparation of dog pancreas membranes (lane 2, PiMM 
20100 cpm; lane 3, PiZZ 23000 cpm). Lanes 4 and 5: 
antibody-precipitated cui-antitrypsin synthesised in the 
presence of dog pancreas membranes and treated with 
endo-,&-N-glucosaminidase (lane 4, PiMM 11000 cpm; 
lane 5, PiZZ 10400 cpm). 
similar for both the PiMM (normal) and PiZZ (ab- 
normal) livers. This therefore implies that the low 
level of circulating Z ai-antitrypsin results from 
defective processing which causes the observed ac- 
cumulation within the cell [I]. In the series of ex- 
March 1983 
Thus we conclude that the Z mutation in 
cui-antitrypsin (Gly -+ Lys at amino acid 342 
[ 1,20,21]) causes a partial blockage in the process- 
ing or transport of the protein subsequent to core 
glycosylation. 
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